QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) An erratum has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sung, M.-H. Articles by Simon, R. Search for Related Content PubMed PubMed Citation Articles by Sung, M.-H. Articles by Simon, R.

In Silico Simulation of Inhibitor Drug Effects on Nuclear Factor-B Pathway Dynamics

Biometric Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

NF-B is a transcription factor family that activates numerous genes that are related to cell survival, apoptosis, and cell migration. Its persistent activity is associated with tumor formation, growth, metastasis, and drug resistance in many cancer types, including lymphoma, colon cancer, and breast cancer. Current therapeutic efforts for inhibiting this central "switch" include using small molecules to block a selected target in this pathway. Recognizing the regulatory network structure of the NF-B pathway, we examine in silico the effects of inhibitors targeting various network components, using a kinetic model of the pathway. By simulating the corresponding perturbed system dynamics, we show the resulting time course of inhibition has distinct target-specific profiles. In particular, greater oscillatory potential exists for inhibition of upstream events than for direct inhibition of NF-B, at low drug concentrations. This phenomenon is observed also when we examine the dynamic effects of the recently approved proteasome inhibitor, bortezomib (PS-341), and compare it with other inhibitors, taking its pharmacokinetics into consideration. Such kinetic analyses of the "drugged" molecular system will facilitate optimal drug target selection and the development of treatment protocols for a molecularly targeted therapy.

Address correspondence to: Myong-Hee Sung, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd. EPN 8146, MSC 7434, Bethesda, MD 20892. E-mail: sungm{at}mail.nih.gov

This article has been cited by other articles:

				D. E. Nelson, C. A. Horton, V. See, J. R. Johnson, G. Nelson, D. G. Spiller, D. B. Kell, and M. R. H. White Response to Comment on "Oscillations in NF-{kappa}B Signaling Control the Dynamics of Gene Expression" Science, April 1, 2005; 308(5718): 52b - 52b. [Full Text] [PDF]